According to Pranzatelli et al. [15], due to the difficulty of identifying the mechanism which triggers OMS especially in recurrent cases, a combined treatment based on GS, ACTH, rituximab or IVIG and cyclophosphamide should be used. The gene discussed is POMC; the disease is opsoclonus-myoclonus syndrome.